FDA Faces Critical Decision on MDMA Therapy for PTSD

Upcoming advisory committee meeting will evaluate the safety and efficacy of ecstasy as a treatment for post-traumatic stress disorder.

FDA staff express concerns over potential bias and safety risks in clinical trials.
MDMA-assisted therapy shows promise but faces scrutiny over trial design and participant blinding.
Veterans' groups and some psychiatrists advocate for the approval due to the lack of effective PTSD treatments.
Allegations of data suppression and trial misconduct complicate the evaluation process.
The FDA may impose strict regulations if the drug is approved, including controlled administration and patient monitoring.